Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

invasive aspergillosis

This page shows the latest invasive aspergillosis news and features for those working in and with pharma, biotech and healthcare.

Shionogi and F2G partner to develop antifungal treatment olorofim

Shionogi and F2G partner to develop antifungal treatment olorofim

F2G developed olorofim as a novel oral antifungal therapy to treat invasive aspergillosis (IA) and other rare mould infections that can cause life-threatening infections, where available treatments have been ineffective. ... Olorofim is currently in a

Latest news

  • Basilea bags $72m upfront from Pfizer for antifungal license Basilea bags $72m upfront from Pfizer for antifungal license

    Cresemba (isavuconazole) was approved in 2015 in both intravenous and oral formulations to treat adults with invasive aspergillosis and invasive mucormycosis, two life-threatening fungal infections typically seen in immunocompromised patients

  • Rare disease therapies head the ‘class of 2015’ Rare disease therapies head the ‘class of 2015’

    isavuconazole. Cresemba. Invasive aspergillosis/mucomycosis. triazole antifungal. Basilea/Astellas. USA. ixazomib. Ninlaro. multiple myeloma.

  • US approval for Astellas’ new antifungal drug Cresemba US approval for Astellas’ new antifungal drug Cresemba

    As these types of fungal infections are rare, the FDA also granted Cresemba orphan drug designations for invasive aspergillosis and invasive mucormycosis. ... The FDA has approved Astellas' antifungal treatment Cresemba (isavuconazonium sulfate) for the

  • FDA panel backs new antifungal Cresemba FDA panel backs new antifungal Cresemba

    The panel gave its blessing to Cresemba ( isavuconazole) in both intravenous and oral formulations as treatments for adults with invasive aspergillosis and invasive mucormycosis, two life-threatening fungal infections typically seen ... Current

  • Orphan status in US for Astellas/ Basilea antifungal Orphan status in US for Astellas/ Basilea antifungal

    Isavuconazole is being developed as a treatment for invasive aspergillosis. The US FDA has given orphan drug status to isavuconazole, a broad-spectrum antifungal being developed by Astellas and partner Basilea ... Invasive aspergillosis is now the

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Basilea has granted an exclusive licence for isavuconazole (an iv and oral antifungal for invasive aspergillosis and mucomycosis) to Asahi Kasei in Japan.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Oxford PharmaGenesis

Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...

Quick links